Last updated: 11/04/2018 04:17:58

Pharmacokinetic study to compare two formulations of paracetamol

GSK study ID
A1900832
See study documents
Clinicaltrials.gov ID
NCT01767428
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Pharmacokinetic Study to Evaluate the Rate and Extent of Absorption of Paracetamol from Two Formulations in an Indian Population.
Trial description: A pharmacokinetic study in healthy volunteers comparing two formulations of paracetamol fast release in fasted state.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:

AUC (0-inf)

Timeframe: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

Cmax

Timeframe: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

AUC (0-t)

Timeframe: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

Secondary outcomes:

Tmax

Timeframe: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

Interventions:
Drug: Paracetamol
Enrollment:
30
Observational study model:
Not applicable
Primary completion date:
2010-30-04
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Fever, Headache Disorders, Pain
Product
paracetamol
Collaborators
Not applicable
Study date(s)
April 2010 to April 2010
Type
Interventional
Phase
1

Participation criteria

Sex
Male
Age
18 - 55 years
Accepts healthy volunteers
Yes
  • Healthy male volunteers aged 18-55yrs willing to give written informed consent for the study
  • BMI must be within the range 18.5 – 24.9 kg/m^2
  • Participant with current or recurrent disease that could affect the action, absorption or disposition of the study medication or clinical or laboratory assessments (e.g. hepatic disorders, renal insufficiency, congestive heart failure)
  • Participant with known or suspected intolerance or hypersensitivity to the study materials
Inclusion and exclusion criteria
Inclusion criteria:
  • Healthy male volunteers aged 18-55yrs willing to give written informed consent for the study
  • BMI must be within the range 18.5 – 24.9 kg/m^2
  • Participant with a minimum weight of 50 kg
Exclusion criteria:
  • Participant with current or recurrent disease that could affect the action, absorption or disposition of the study medication or clinical or laboratory assessments (e.g. hepatic disorders, renal insufficiency, congestive heart failure)
  • Participant with known or suspected intolerance or hypersensitivity to the study materials
  • Participant who are vegetarian
  • Participant smoking more than five cigarettes a day

Trial location(s)

No location data available.

Study documents

Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Completed
Actual primary completion date
2010-30-04
Actual study completion date
2010-30-04

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website